With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

As a result, the positive rate of amyloid beta protein, which shows the risk of amyloid accumulation, a causative agent of ...

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...

This increase correlated with changes in biomarkers associated with neurodegenerative diseases like Alzheimer’s, such as ...